In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.

Inclusion Criteria:

• Fully understood this study and voluntarily signed the informed consent form (ICF);

  -≥ 18 years and ≤ 75 years old;

• ECOG score 0-1;

• Non-squamous NSCLC;

• stage IV;

• EGFR and ALK negative;

• Treatment-naive;

• According to RECIST1.1 criteria, there are measurable or evaluable lesions.

Exclusion Criteria:

• Tumor histology or cytology confirmed that it was associated with squamous cell carcinoma or small cell lung cancer;
• Patients with severe organ dysfunction were indicated by examination, Exclude subjects with any active, known or suspected autoimmune diseases;
• The estimated survival time is less than 3 months.